China announced the revocation of the GeneScience Pharmaceutical license to manufacturer Jintropin brand human growth hormone. This represents a major success in efforts towards the internationalization of steroid and doping law by the United States. The U.S. federal government indicted CEO Lei Jin and GeneScience Pharmaceutical Inc. last fall as part of Operation Raw Deal (”China Cracks Down on Drug Companies,” June 19).
One of the drugmakers that China named Wednesday was GeneScience Pharmaceutical, which is based in northern China and run by an American-educated executive. Last September, a federal grand jury in Rhode Island indicted the company for illegally distributing millions of dollars in human growth hormones in the United States. The company had denied the allegation, but its American agent pleaded guilty in February to conspiracy to distribute H.G.H.
